Table 5.
Summary statistics for pravastatin and boceprevir pharmacokinetic parameters
| Drug | Parameter | Treatment | n | Geometric meana | Comparison | GMR | 90% CI for GMR |
|---|---|---|---|---|---|---|---|
| Pravastatinb | Cmax (ng/ml) | Pravastatin + boceprevir | 9 | 44.7 | Pravastatin + boceprevir vs pravastatin alone | 1.49 | 1.03–2.14 |
| Pravastatin alone | 10 | 30.1 | |||||
| AUCinf (ng · h/ml) | Pravastatin + boceprevir | 7 | 142 | Pravastatin + boceprevir vs pravastatin alone | 1.63 | 1.03–2.58 | |
| Pravastatin alone | 6 | 87.3 | |||||
| Boceprevirc | Cmax (ng/ml) | Boceprevir + pravastatin | 9 | 1,806 | Boceprevir + pravastatin vs boceprevir alone | 0.928 | 0.828–1.04 |
| Pravastatin alone | 9 | 1,947 | |||||
| AUC0–8 (ng · h/ml) | Boceprevir + pravastatin | 9 | 6,555 | Boceprevir + pravastatin vs boceprevir alone | 0.951 | 0.892–1.01 | |
| Pravastatin alone | 9 | 6,889 |
a
Model-based (least-squares) geometric mean based on mixed-effect model extracting the effect due to treatment as the fixed effect and subject as the random effect.
b
Single-dose pravastatin with and without multiple-dose boceprevir.
c
Multiple-dose boceprevir with or without single-dose pravastatin.